Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

(2017) Kanaga Sabapathy et al.   Nature Reviews Clinical Oncology

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies

(2017) Anne Perdrix et al.   Cancers

Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism

(2016) Zhihong Ai et al.   CANCER LETTERS

TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value

(2016) Christophe Deben et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer

(2016) Åsa Fransson et al.   Journal of Ovarian Research

Regulation of Hypoxia-Inducible Factor-1a by Reactive Oxygen Species : New Developments in an Old Debate

(2015) Shahrzad Movafagh et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization

(2015) Carina Fischer et al.   Molecular Cancer

The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression

(2015) Ivano Amelio et al.   TRENDS IN BIOCHEMICAL SCIENCES

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells

(2015) N Mohell et al.   Cell Death & Disease

The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer

(2015) Christophe Deben et al.   Oncotarget

Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells

(2015) Hui-Mei Wu et al.   Scientific Reports

HIF-1α pathway: role, regulation and intervention for cancer therapy

(2015) Georgina N. Masoud et al.   Acta Pharmaceutica Sinica B

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

(2014) B. Tessoulin et al.   BLOOD

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs

(2014) Tao Zhao et al.   Scientific Reports

Hypoxia, Mn-SOD and H2O2 regulate p53 reactivation and PRIMA-1 toxicity irrespective of p53 status in human breast cancer cells

(2012) Manuel Rieber et al.   BIOCHEMICAL PHARMACOLOGY

Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells

(2011) Christoph Wohlkoenig et al.   CANCER LETTERS

Molecular mechanisms of cisplatin resistance

(2011) L Galluzzi et al.   ONCOGENE

Reciprocal influence of the p53 and the hypoxic pathways

(2011) A Sermeus et al.   Cell Death & Disease

Hypoxia and mitochondrial oxidative metabolism

(2010) Giancarlo Solaini et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells

(2008) Seung-Nam Jung et al.   CARCINOGENESIS